Corticosteroids and community-acquired pneumonia

Clinical Pulmonary Medicine

Volumn 10, Issue 5, 2003, Pages 255-262

  Solé Violán, Jorge ^a   Marcos y Ramos, Alberto ^a   Aspa Marco, Javier ^b   Rodríguez de Castro, Felipe ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Community acquired pneumonia; Corticosteroids; Cytokines; Inflammation; Mortality; Pulmonary host defenses

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CORTICOTROPIN; CYTOKINE; FLUDROCORTISONE; HYDROCORTISONE; HYPERTENSIVE FACTOR; METHYLPREDNISOLONE; PENICILLIN DERIVATIVE; PREDNISONE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; BRONCHIOLITIS; CLINICAL TRIAL; COMMUNICABLE DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HOST RESISTANCE; HUMAN; INFLAMMATION; OPTIMAL DRUG DOSE; OUTCOMES RESEARCH; PATIENT SELECTION; PNEUMONIA; REVIEW; SEPSIS; TREATMENT INDICATION;

EID: 0141563763     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000087611.74932.d2     Document Type: Review

References (50)

1. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
2. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24:163-172.
3. Jantz MA, Sahn SA. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med. 1999;160:1079-1100.
4. Torres A, El Ebiary M, Montón C. The inflammatory response in pneumonia. In: Vincent JL, eds. Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer-Velag; 1997:595-606.
5. Kolling UK, Hansen F, Braun J, et al. Leucocyte response and anti-inflammatory cytokines in community-acquired pneumonia. Thorax. 2001;56:121-125.
6. Cox G. IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis in neutrophils. Am J Physiol. 1996;271:L566-L571.
7. Dehoux MS, Boutten A, Ostinelli J, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1994;150:710-716.
8. van der Poll T, Keogh CV, Buurman WA, et al. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med. 1997;155:603-608.
9. Laichalk LL, Kunkel SL, Strieter RM, et al. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumoniae. Infect Immun. 1996;64:5211-5218.
10. Boutten A, Dehoux MS, Seta N, et al. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1996;153:336-342.
11. Montón C, Torres A, El-Ebiary M, et al. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med. 1999;27:1745-1753.
12. Glynn P, Coakley R, Kilgallen I, et al. Circulating interleukin 6 and interleukin 10 in community-acquired pneumonia. Thorax. 1999;54:51-55.
13. van der Poll T, Marchant A, Keogh CV, et al. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis. 1996;174:994-1000.
14. Bauer TT, Montón C, Torres A, et al. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia and controls. Thorax. 2000;55:46-52.
15. Goldman M, Marchant A. Interleukin-10 production during septic shock. In: Vincent JL. Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer-Verlag; 1996:105-110.
16. Schultz MJ, Knapp S, van der Poll T. Regulatory role of alveolar macrophages and cytokines in pulmonary host defense. In: Vincent JL. Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer-Verlag; 2002:65-76.
17. Annane D. Corticosteroids for septic shock. Crit Care Med. 2001;29: S117-S120.
18. Annane D, Bollaert PE, Lagente V, et al. Corticosteroids in severe sepsis. Clin Pulmonary Med. 2001;8:273-278.
19. Saito T, Takanashi M, Gallagher E, et al. Corticosteroids' effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med. 1995;21:204-210.
20. Skerrett SJ, Park DR. Anti-inflammatory treatment of acute and chronic pneumonia. Semin Respir Infect. 2001;16:76-84.
21. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis. 1989;69:954-963.
22. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990;323:1451-1457.
23. Montaner JS, Lawson LM, Levitt N, et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome (AIDS). Ann Intern Med. 1990;113:14-20.
24. Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial. N Engl J Med. 1990;323:1444-1450.
25. Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218-220.
26. Wagner HN, Bennett IL Jr, Lasagna L, et al. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp. 1956;98:197-215.
27. Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest. 1993;104:389-392.
28. Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest. 1998;114:426-431.
29. Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA. 1963;183:462-465.
30. Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections: a double-blind study. N Engl J Med. 1971;284:1248-1250.
31. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976;184:333-341.
32. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg. 1984;119:537-541.
33. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med. 1984;311:1137-1143.
34. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
35. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317:659-665.
36. Luce JM, Montgomery AB, Marks JD, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138:62-68.
37. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23:1430-1439.
38. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995;23:1294-1303.
39. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26:645-650.
40. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double blind, single center study. Crit Care Med. 1999;27:723-732.
41. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
42. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000;283:1038-1045.
43. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest. 1997;111:1306-1321.
44. Elias JA, Freundlich B, Kern JA, et al. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest. 1990;97:1439-1445.
45. Weigelt JA, Norcross JF, Borman KR, et al. Early steroid therapy for respiratory failure. Arch Surg. 1985;120:536-540.
46. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565-1570.
47. Luce JM. Corticoids in ARDS: an evidence-based review. Crit Care Clin. 2002;18:79-89.
48. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolved acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280:159-165.
49. Epler GR, Colby TV, McLoud TC, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med. 1985;312:152-158.
50. Cordier JF. Cryptogenetic organizing pneumonitis: bronchiolitis obliterans organizing pneumonia. Clin Chest Med. 1993;14:677-692.